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Abstract: Brain tumors are a heterogeneous group of neoplasms ranging from almost benign to
highly aggressive phenotypes. The malignancy of these tumors mostly relies on gene expression
reprogramming, which is frequently accompanied by the aberrant regulation of RNA processing
mechanisms. In brain tumors, defects in alternative splicing result either from the dysregulation
of expression and activity of splicing factors, or from mutations in the genes encoding splicing
machinery components. Aberrant splicing regulation can generate dysfunctional proteins that lead to
modification of fundamental physiological cellular processes, thus contributing to the development or
progression of brain tumors. Herein, we summarize the current knowledge on splicing abnormalities
in brain tumors and how these alterations contribute to the disease by sustaining proliferative
signaling, escaping growth suppressors, or establishing a tumor microenvironment that fosters
angiogenesis and intercellular communications. Lastly, we review recent efforts aimed at developing
novel splicing-targeted cancer therapies, which employ oligonucleotide-based approaches or chemical
modulators of alternative splicing that elicit an impact on brain tumor biology.
Keywords: alternative splicing; brain tumors; splicing factors; EGFR signaling; hippo signaling;
tumor microenvironment; PRMT5
1. Introduction
Tumors of the central nervous system (CNS) are a heterogeneous group of diseases that are classified
on the basis of molecular parameters and histopathological characteristics. A comprehensive classification
of CNS tumors was first established by the World Health Organization (WHO) in 2016 [1], substituting
previous ones that were based only on histological features. The incorporation of well-established
genetic parameters in the new guidelines has particularly improved the classification of diffuse gliomas
and embryonal tumors, such as medulloblastoma [1]. While the identification and validation of
further objective molecular parameters are still necessary to improve the accuracy of the current
classification [1], changes made so far have highlighted the importance of elucidating molecular aspects
of CNS tumors to better stratify patients. Among CNS tumors, herein we mainly focus on gliomas and
medulloblastomas, for which a clear involvement of splicing dysregulation has been described.
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Diffuse gliomas represent a broad category of brain and spinal cord tumors that arise from glial
cells. According to the WHO classification, they are subdivided in grade II and III astrocytomas,
grade II and III oligodendrogliomas and grade IV glioblastomas (Table 1) [1].
Table 1. Grading of CNS tumors mentioned in this review according to WHO guidelines [1].
Tumor Type Grade
Diffuse Astrocytic and Oligodendroglial Tumors
Diffuse astrocytoma (IDHmut) II
Oligodendroglioma (IDHmut-1p/19q deleted) II
Anaplastic astrocytoma (IDHmut) III
Anaplastic Oligodendroglioma (IDHmut-1p/19q deleted) III
Diffuse midline Glioma (H3K27Mmut) IV
Glioblastoma (IDHwt) IV
Glioblastoma (IDHmut) IV
Ependymal Tumor
Subependymoma I
Myxopapillary ependymoma I
Ependymoma II
Ependymoma (RELA fusion-positive) II/III
Anaplastic Ependymoma III
Embryonal Tumors
Medulloblastoma IV
Embryonal tumors with multilayered rosette IV
Medulloepithelioma IV
CNS Embryonal tumors IV
Atypical teratoid/rhabdoid tumor IV
CNS Embryonal tumors with rhabdoid features IV
Glioblastoma (GBM) arises from the astrocytic lineage [1] and accounts for more than 60% of all
brain tumors in adults [2]. It is associated with very poor prognosis and displays a median survival of
one year [3]. Current treatments include tumor resection, radiation and chemotherapeutic treatment
with temozolomide [4]. Despite these invasive therapies, GBMs almost invariably relapse due to
their highly resistant and infiltrative nature [5]. Several prognostic biomarkers allow stratification of
GBM patients. For instance, the methylation status of O6-methylguanine methyltransferase (MGMT)
gene promoter predicts benefit from temozolomide chemotherapy. Other molecular markers used in
patient stratification are the mutational status of the isocitrate dehydrogenase (IDH) and epidermal
growth factor receptor (EGFR) genes [6]. IDH mutations are found in ~5–10% of GBM patients and are
associated with better outcomes [7]. On the other hand, ~25% of GBM patients that are wild-type for
IDH show EGFR amplification, with half of these tumors harboring a deletion in the gene that yields a
receptor endowed with ligand-independent activity [8].
Grade IV medulloblastoma (MB, also referred to as primitive neuroectodermal tumor) arises
from the primitive or embryonal cells of the cerebellum (Table 1). MB is the most common malignant
brain tumor in children [9] with a culminating incidence before the age of five [10]. They are treated
using combined therapeutic approaches, which include surgical resection as well as radio- and chemo-
therapy [11]. Although these treatments strongly improve overall survival rates of MB patients, they
are extremely aggressive and devastating for these young patients. MBs are subdivided into four
subgroups on the basis on distinct molecular parameters, namely wingless-activated (WNT), sonic
hedgehog-activated (SHH), Group 3, and Group 4 MBs [12]. Among them, WNT MB displays the most
favorable prognosis, whereas Group 3 shows the worst prognosis, and SHH and Group 4 MBs are
characterized by an intermediated clinical course [13,14].
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2. Dysregulation of Splicing in Human Cancers
Besides genetic alterations, the deregulation of gene expression programs is a well-established
hallmark of cancer [15]. The aberrant expression of oncogenic and tumor-suppressor transcription
factors often underlies the alteration of transcriptional and post-transcriptional mechanisms in cancer
cells. Furthermore, the dysregulation of splicing regulatory mechanisms has clearly emerged as a typical
feature of cancer cells, which can either drive or contribute to tumor onset and progression [16,17].
High-throughput sequencing studies in the last decade have shown that nearly all human genes
undergo alternative splicing regulation [18,19]. This mechanism is clearly advantageous for eukaryotic
cells as it endows them with a plastic genome and contributes to the expansion of their proteome
diversity. Indeed, splicing choices can be fine-tuned in the cell by the activation of signal transduction
pathways in response to both external and endogenous cues. In this way, cells modulate their proteome
to withstand changes in the surrounding environment, or in response to the activation of a specific
differentiation program [20]. Nevertheless, its remarkable flexibility represents a risk factor, and splicing
dysregulation concurs with many human diseases [20] including cancer [16,17]. The aberrant splicing
events occurring in cancer cells often lead to generation of protein variants displaying altered function,
which can contribute to tumorigenesis [16]. Failure to properly recognize a splice site is often the
result of mutations in the splice site sequence and/or of the dysregulation of splicing factor expression
in cancer cells. Moreover, mutations in genes encoding core proteins and RNAs of the splicing
machinery have recently emerged as oncogenic drivers which promote widespread transcriptome
modifications [16,21]. Herein, we review the current knowledge concerning splicing dysregulation
in brain tumors, with particular attention paid to pro-oncogenic processes underlying cancer onset
and progression.
3. Regulation of Alternative Splicing
Splicing is operated by a ribonucleoprotein complex, named spliceosome, which catalyzes two
successive trans-esterification reactions at the exon–intron boundaries, thus removing introns and
joining adjacent exons [22]. Canonical consensus sequences, including the 5′ and 3′ splice sites (ss),
the branch point and the polypyrimidine tract, contribute to exon recognition by driving stepwise
recruitment of spliceosomal small nuclear ribonucleoproteins (U1, U2, U4, U5, and U6 snRNPs).
The base pairing of the U1 small nuclear RNA (snRNA) to the 5′ss and the binding of splicing factor 1
(SF1) to the branch point are the first events. The successive recruitment of the U2AF65/U2AF35
dimer to the polypyrimidine tract and to the 3′ss, respectively, facilitates the replacement of SF1
with the U2 snRNP. This complex in turn recruits U4/U6-U5 snRNPs and promotes the formation of
catalytically active spliceosome complexes that mediate trans-esterification reactions [23]. However,
since the sequences recognized by the spliceosome are short and degenerate, and human exons are
generally much shorter (~150 bp) than introns (>1000 bp), proper exon recognition is a difficult
task that requires additional cis-regulatory RNA elements and trans-acting factors [22,24]. Moreover,
competition between trans-acting factors for binding to cis-regulatory RNA elements can result in the
alternative selection of exons in the mature mRNA. Indeed, while many exons are constitutively spliced,
nearly all human genes also contain variant exons that can be alternatively spliced [18,19], yielding
mRNA species that could present a distinct regulatory fate [25] and/or give rise to multiple protein
products from a single gene [26,27]. Alternative splicing events can affect the entire exon (cassette
exon) or part of it, through the usage of alternative 5′ and 3′ ss that are present in a variant exon.
Furthermore, mutually exclusive exons can be alternatively spliced, while introns can be retained in the
mature transcript. Lastly, alternative first exons can be selected in genes bearing multiple transcription
start sites, whereas the usage of multiple polyadenylation sites can yield alternative last exons [17].
The combination of one or more of these alternative splicing types allows each human gene to encode
multiple splice variants and proteins, thus enhancing the coding potential of the genome [20,22,24].
The cis-regulatory RNA elements can be distinguished in exonic or intronic splicing enhancers
or silencers. These sequences are recognized by trans-acting splicing factors that modulate the
Cells 2020, 9, 10 4 of 21
recruitment of spliceosome components near the target exon. The major families of proteins involved
in splicing regulation are the serine-arginine rich (SR) proteins [28] and the heterogeneous nuclear
ribonucleoproteins (hnRNPs) [29]. SR proteins preferentially bind enhancer elements and exhibit a
positive role in splicing regulation. Conversely, the binding of hnRNPs to silencer elements generally
represses exon inclusion. SR proteins and hnRNPs can compete for binding to cis-regulatory RNA
elements and/or for the recruitment of spliceosome component(s). Furthermore, the activity of many
splicing factors is regulated by the reversible phosphorylation mediated by specific protein kinases,
which fine-tunes their activity in response to the activation of signaling pathways [30]. Phosphorylation
impacts most features of splicing factors, from the affinity for their target RNA, to the regulation of
their subcellular localization and interaction with co-factors [30]. Moreover, alternative splicing is also
influenced by the context of the cis-regulatory RNA elements [31–35], RNA structure [36], transcription
rate, and the chromatin epigenetic signature [37,38].
4. Splicing Dysregulation in Brain Tumors
Deregulation of the activity and/or expression of several splicing factors in brain tumors was
shown to elicit a significant impact on their transcriptome [39–42]. Current knowledge mainly relates
to GBM, the most common type of adult brain tumors. For instance, the spliceosome component
SmB/B’ (SNRPB) is up-regulated and exerts a pro-oncogenic role in GBM by controlling the expression
and splicing of several genes associated with gliomagenesis [42] (Table 2).
Similarly, the high expression of PTBP1 (also known as hnRNPI) and/or its amplification in
GBM maintain progenitor-specific splicing patterns that counteract tumor suppressor functions
and favor tumor progression [43]. Among other events, PTBP1 promotes the aberrant splicing of
Brahma/SWI2-related gene 1 (BRG)-associated factor (BAF45d) [44], a co-transcriptional regulator
involved in brain development (Table 2). Importantly, the proto-oncogene c-MYC was shown to
orchestrate the concomitant up-regulation of PTBP1 and two other hnRNPs (hnRNPA1, hnRNPA2)
in GBM [45], which cooperate in the splicing regulation of the pyruvate kinase gene (PKM) [45,46]
(Table 2). PKM catalyzes the last step of the glycolytic pathway by promoting the conversion of
phosphoenolpyruvate to pyruvate. Mutually exclusive splicing of exon 9 or 10 in PKM yields either
the PKM1 or the PKM2 isoform, respectively. PKM1 is the adult isoform and promotes oxidative
phosphorylation, whereas PKM2 is prevalently expressed during embryogenesis and promotes
aerobic glycolysis. The binding of hnRNPA1, hnRNPA2, and PTBP1 to sequences flanking exon 9
promotes the inclusion of exon 10 and expression of PKM2, thus ensuring high glycolytic flux in GBM
cells [45,46]. Another splicing factor contributing to this metabolic switch is the SR protein SRSF3,
which is also up-regulated in gliomas and sustains glioma stem cells (GSCs) growth, self-renewal,
and tumorigenicity [47]. Whole transcriptome analysis revealed a role for SRSF3 as widespread
modulator of gene expression and splicing in GBM (Table 2). SRSF3 also promotes exon 10 inclusion
and PKM2 expression [48]. Notably, reverting this splicing switch by transducing an exon 10-targeting
antisense oligonucleotide (ASO) induced apoptosis in GBM cells [49] (Table 2), suggesting their
addiction to aerobic glycolysis.
Splicing regulation can also result in opposite functions of the cancer-specific protein variant.
For instance, the cyclin-dependent kinase (Cdk)-associated protein phosphatase KAP dephosphorylates
CDK2 and inhibits cell cycle progression. However, its aberrant splicing in GBM cells yields a dominant
negative KAP variant that increases proliferation and migration, thus contributing to malignancy [50]
(Table 2). Likewise, the up-regulation of hnRNPH in GBM alters the splicing of the anti-apoptotic
isoform MAP-kinase activating death domain protein (MADD), thus switching the function of the
TNF-α/TRAIL-induced pathway from apoptosis to proliferation [51] (Table 2). On the other hand, SRSF1
promotes splicing of the membrane-localized full-length isoform of class I Myosin 1B (MYO1B-FL) over
a cytoplasmic truncated isoform (MYO1B-T) [35] (Table 2). Interestingly, while MYO1B-FL promotes cell
proliferation, survival, and invasion, MYO1B-T lacks these pro-oncogenic features. This antagonistic
behavior of MYO1B splice variants has been ascribed to the ability of MYO1B-FL to directly recruit
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the phosphoinositide 3 kinase (PI3K) at the plasma membrane, thus activating the PDK1/AKT and
PAK/LIMK signaling pathways [35]. Since up-regulation of SRSF1 associates with tumor progression
and poor prognosis in gliomas [35], these observations suggest that the SRSF1-guided splicing switch
contributes to malignancy by fueling proliferative pathways.
In addition to mutations in protein coding genes, recent evidence suggests that the dysregulation
of splicing in human cancers may also arise from mutations in non-coding RNAs of the spliceosome.
Indeed, mutations in U1 snRNA have been identified across several cancer types and were suggested
to act as oncogenic drivers [21]. For instance, 28 of the 164 nucleotides (nt) present in the U1 snRNA are
recurrently mutated in bladder cancer. On the other hand, the third nt in U1 snRNA is mutated in 97%
and 25% of cases of adult and adolescent SHH-MB, respectively, and the mutation correlates with poor
prognosis [52]. Recognition of 5′ss by the U1 snRNP is the first event occurring during splicing [23].
It requires base pairing between a stretch of 8 nt (3-10 nt) of the U1 snRNA with a complementary
region at the 5′ss (from +6 to -2 nt from 5′ss) of the pre-mRNA. In this context, the A in the third
position (nt 3) of U1 snRNA anneals with the U at +6 position in the intron of the pre-mRNA (Figure 1).
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Figure 1. Schematic representation of alternative splicing events mediated by U1 snRNA A>G transition
in medulloblastoma. Base-pairing between the wild-type 5′ss recognition sequence (3–10 nt) of U1
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Thus, the A>G transition at the third nt of the mutated U1 snRNA favors G-C base-pairing and
increases the occurrence of cryptic alternative 5′ splicing events and/or intron retention. Interestingly,
such a mutation correlated with the splicing-dependent inactivation of the PTCH1 tumor-suppressor
gene and activation of the GLI2 and CCND2 oncogenes in SHH-MB, supporting the biological relevance
of U1 snRNA mutation in this tumor [52].
Although splicing dysregulation in cancer is generally believed to promote tumorigenesis and
more aggressive phenotypes, it may also represent a targetable vulnerability. In this regard, recent
findings have highlighted that GBM cells accumulate transcripts with retained introns, which require
high activity of the arginine methyl-transferase PRMT5 to be properly spliced. Inhibition of PRMT5
negatively impacted GBM growth by impairing intron removal in genes involved in proliferation [53].
Thus, dependency on PRMT5-induced splicing may represent a vulnerability of GBM that can be
exploited therapeutically (see below). This concept may also hold true for other MYCN-amplified
brain tumors, as amplification of MYC generally correlates with increase intron retention and higher
dependency on the efficiency of the splicing machinery [54].
5. Biological Relevance of Alternative Splicing Regulation in Brain Tumors
Cancer-related splicing dysregulation often alters the activity of genes governing a broad spectrum
of physiological processes, thus sustaining cell behaviors that predispose to cancer onset and progression.
Cellular oncogenic features can evolve from a combination of abnormalities, which affect key signaling
pathways and interaction with the tumor microenvironment. Herein, we summarize some examples
of how aberrant splicing can impact these processes in brain tumors.
5.1. EGFR Signaling Pathway
The EGFR, also known as ErbB1/Her1 [55], is a key factor for brain tumors as it supports the
proliferation and stemness of neural progenitor cells from which these tumors originate. Upon EGF
binding, the EGFR undergoes conformational changes and autophosphorylation, thus favoring the binding
of the regulatory subunit of PI3K and activation of a signaling cascade that leads to phosphorylation
and activation of AKT [56]. In turn, the PI3K/AKT pathway plays a pivotal role in the regulation of
key biological processes in brain tumors, including cell proliferation, metabolism, survival, migration
and angiogenesis [57]. The EGFR gene is often amplified in GBM patients, with a subgroup of them
showing aberrant expression of an oncogenic variant named EGFRvIII [58]. This variant arises from
an in-frame genomic deletion of the exons 2–7 encoding for the extracellular ligand binding domain.
As a consequence, EGFRvIII displays constitutive activation, high oncogenic potential and correlates
with poor prognosis [58–61]. Transcriptomic analysis performed in GBM cells reveals that aberrant
EGFR/EGFRvIII signaling leads to up-regulation of the expression of genes that are target of the c-MYC
oncogene through a complex and interconnected network [62]. For instance, up-regulation of hnRNPA1
promotes splicing of a truncated isoform of MAX (∆MAX), a core MYC cofactor. ∆MAX enhances
the expression of glycolytic genes and favors glucose uptake, glucose-dependent cell proliferation
and GBM growth [62] (Figure 2 and Table 2). The expression of hnRNPA1 positively associates with
that of EGFRvIII and c-MYC-regulated glycolytic genes in GBM patients and this signature correlates
with short overall survival [62]. These findings suggest that aberrant EGFR signaling promotes
splicing dysregulation, which in turn amplifies EGFR signaling and metabolic changes that support
GBM growth.
Inhibition of EGFR degradation also contributes to malignancy in brain tumors [63]. Upon
endocytic internalization, EGFR is trafficked from early endosomes to late endosomes/lysosomes for
degradation by the cargo transport GTPase protein Rab7A. Alternatively, EGFR is recycled to the
cell membrane to maintain EGFR signaling [63]. Alteration of the balance between degradation and
recycling affects EGFR signaling in physiological and pathological conditions. Notably, the up-regulation
of PTBP1 in GBM alters the splicing of Annexin A7 (ANXA7), a membrane-bound tumor suppressor
protein involved in endosomal organization and function [64]. PTBP1 promotes the skipping of exon 6
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in ANXA7 and expression of this isoform diminishes the endosomal internalization of EGFR (Figure 2),
thus enhancing signaling during tumor progression [43] (Table 2).Cells 2019, 8, x FOR PEER REVIEW  7  of  22 
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Figure 2. Dysregulation of alternative splicing sustains EGFR/EGFRvIII signaling and metabolism
reprogramming in brain tumors. Stimulation of EGFR, and/or expression of the constitutive active
EGFRvIII isoform, activates MYC-dependent expression of hnRNP proteins promoting alternative
splicing of PKM2 and ∆MAX isoforms. High level of PKM2 and ∆MAX ensures high glycolytic flux
and expression of GLUT1, GLUT3, PDK1 and HK2 genes, respectively, sustaining glucose-dependent
cell proliferation. Concurrently, CD44s expression and PTBP1-mediated splicing of ANXA7-I2 isoform
amplifies EGFR signaling by reducing lysosomal degradation of activated receptor. EGFR: epidermal
growth factor receptor; EGFRvIII: epidermal growth factor receptor variant III; EGF: epidermal
growth factor; hnRNPA1: heterogeneous nuclear ribonucleoprotein A1; hnRNPA2: heterogeneous
nuclear ribonucleoprotein A2; PTBP1: Polypyrimidine tract-binding protein 1; SRSF3: serine and
arginine rich splicing factor 3; PKM: pyruvate kinase; PKM2: pyruvate kinase isozymes M2; GLUT1:
glucose transporter 1; GLUT3: glucose transporter 3; PEP: phosphoenolpyruvate; ANXA7: annexin
A7; ANXA7-I2: annexin A7 isoform 2; PDK1: pyruvate Dehydrogenase Kinase 1; LDHA: lactate
dehydrogenase A; HK2: hexokinase 2. MAX: myc-associated factor X; ∆MAX: delta myc-associated
factor X.
Alternative splicing of the CD44 gene also modulates EGFR degradation in GBM. CD44 is a
transmembrane glycoprotein receptor that controls cell proliferation, adhesion, migration, signaling,
and survival. The CD44 gene comprises 20 exons, with 10 of them being regulated by alternative
splicing. The standard CD44 isoform (CD44s) contains only the constitutive xons, wher as multiple
CD44 variant isoforms (CD44v) derive from differential assortments of the other alter atively spliced
exons [65]. In GBM, CD44s, but not CD44v, a tenuates EGFR degradatio , resulting n enhanced
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AKT signaling. CD44s internalizes from cell surface to the endosomal compartments and inhibits
Rab7A-mediated EGFR degradation [66] (Figure 2 and Table 2). Accordingly, CD44s expression
correlates with highly invasive behavior and poor prognosis [67].
5.2. Hippo Signaling Pathway
The Hippo pathway is a key regulator of organ size and tissue homeostasis during development [68].
Activation of the Hippo pathway promotes phosphorylation of the large tumor suppressor homolog 1/2
(LATS1/2) by the mammalian Ste20-like kinases 1/2 (MST1/2). Once activated, LATS1/2 phosphorylates
the yes-associated protein (YAP) and the transcriptional co-activator with PDZ binding motif (TAZ),
which are the key effectors of the pathway. Phosphorylation of the YAP/TAZ complex sequesters it in
the cytoplasm and targets it for degradation, thus halting cell proliferation. Conversely, Hippo pathway
inhibition leads to nuclear translocation of YAP/TAZ and activation of a transcriptional program
guided by the TEAD family transcription factors that sustains cell proliferation [68]. Deregulation of
the Hippo pathway contributes to development of several cancers [69], including brain tumors [70].
For instance, YAP gene amplification was shown to contribute to SHH-MB [71], whereas YAP gene
fusions with MAMLD1 or C11orf95 have been identified in ependymal tumors. Since neural stem
cells carrying the YAP-C11orf95 fusion gene form brain tumors when grafted into mice, such genetic
aberrations were proposed to promote tumorigenesis [72].
Splicing factors can impact the expression of components of the Hippo pathway in brain tumors.
For instance, the ubiquitin specific protease 39 (USP39), promotes RNA processing and expression of
TAZ, thus favoring glioma oncogenic features in vitro and in vivo [73] (Table 2). Furthermore, recent
evidence indicates that gliomas express high levels of a splice variant of the prostate transmembrane
(TM) protein, androgen induced 1 (PMEPA1) called PMEPA1a, which promotes degradation of the
tumor suppressor LATS1 protein. The decreased levels of LATS1 unleash YAP activity and support
pro-oncogenic features in glioma cells [74] (Table 2). In line with these observations, the splicing factor
USP39 is up-regulated in high-grade gliomas [73], whereas reduced levels of LATS1 associate with
poor prognosis in glioma patients [75]. Although the mechanisms driving these splicing-related events
(i.e., up-regulation of USP39 and splicing of PMEPA1a) are still unknown, these studies suggest that
splicing dysregulation impacts a key developmental program by altering the equilibrium of the Hippo
pathway during gliomagenesis.
5.3. Tumor Microenvironment
Crosstalk between tumor cells and the associated tumor microenvironment (TME) strongly
influences cancer initiation, progression, and prognosis [76]. TME comprises several infiltrating
fibroblasts and immune cells as well as extracellular components (cytokines, growth factors, hormones,
extracellular matrix, etc.) that influence tumor cell biology. Notably, brain tumors hardly colonize
outside the CNS, suggesting that the TME establishes a tumor niche that sustains tumor growth and
progression. Another peculiarity of brain TME is the presence of a blood-brain barrier, which affects
the composition of the extracellular matrix (ECM) as well as the population of resident cells [77].
Mounting evidence indicates that regulation of alternative splicing contributes to the establishment of
a specific TME in brain tumors and affects the outcome of the disease.
In the brain, the main constituents of ECM include proteoglycans, glycoproteins, and
glycosaminoglycans, as heparan sulfate proteoglycans (HSPGs) and hyaluronic acid (HA) [77]. HSPGs
sequester angiogenic heparin-binding growth factors, such as fibroblast growth factors (FGFs) and
vascular endothelial growth factors (VEGFs), which are subsequently released by heparanase (HSPE),
thus modulating their availability in the TME [78]. Up-regulation of HPSE in GBM has been associated
to the expression of a truncated splice variant of the transcription factor GLI1 [79,80], the terminal
effectors of the SHH pathway [81]. Alternative splicing of human GLI1 pre-mRNA yields either the
full length isoform or two shorter isoforms named GLI1DN [82] and tGLI1 [80]. The tGLI1 splice
variant contains a small in-frame deletion and drives a different transcriptional program with respect
Cells 2020, 9, 10 9 of 21
to full-length GLI1 [80]. Indeed, tGLI1 sustains GBM angiogenesis and growth by promoting the
expression of VEGFA and VEGF receptor 2 (VEGFR2) in both GBM and MB [79] (Table 2). Furthermore,
tGLI1 is predominantly activated in the highly aggressive mesenchymal subtype of GBM and in GSCs,
suggesting its contribution to the acquisition of a more malignant GBM phenotype [83].
The high vascularity that characterizes brain tumors is affected by the splicing dysregulation of
VEGF variants. The VEGFA gene consists of eight exons and its alternative splicing yields numerous
isoforms displaying different ability to bind heparin and heparin sulphate proteoglycans located
on the cell surface and the ECM [84]. In particular, the usage of alternative 3’ss in VEGFA exon 8
generates either the pro-angiogenic VEGFXXXa (usage of distal 3’ss) or the anti-angiogenic VEGFXXXb
(usage of proximal 3’ss) variant (where xxx represents the amino acid number of mature protein) [84].
Moreover, the presence of an alternative translation initiation CUG codon leads to the synthesis of
long VEGF (L-VEGF) [84]. Two splice variants of L-VEGF (L-VEGF144a and L-VEGF138a) have been
described in GBM [85,86]. The L-VEGF144a variant lacks part of exon 1 and exons 2 to 5, retains exons 7
and 8, and utilizes an in frame alternative intronic 3’ss of exon 6a. This variant was found in GBM
patients and it is associated with worse response rate to combined treatments including bevacizumab,
temozolomide and radiotherapy (Table 2). Notably, L-VEGF144a expression was not associated with
different outcome in patients receiving the standard therapy (temozolomide and radiotherapy) [86],
suggesting that the VEGF epitope targeted by bevacizumab is absent in L-VEGF144a. Thus, the different
response to these therapies indicates that expression of this splice variant could be used as prognostic
factor for bevacizumab treatment, a currently Food and Drug administration (FDA)-approved therapy
for GBM [87].
Splicing regulation also affects the reciprocal interaction between tumor cells and TME during
migration and invasion [88]. The long splice variant of the scaffold protein Intersectin 1 (ITSN1-L)
is highly enriched in neurons, whereas the short ITSN1-S isoform is mainly expressed by astrocytes
and microglia [89]. The expression of ITSN1-L was negatively correlated with brain tumor grade
and prognosis in glioma. By contrast, expression of ITSN1-S was elevated in glioma [90]. Notably,
while these isoforms did not shown differences in promoting cell growth, only ITSN1-L was capable to
inhibit cell migration and invasion by affecting HDAC6-mediated stability of microtubules. Moreover,
ITSN1-L was shown to attenuate cell-substrate adhesion and strengthen cell-cell junctions [90] (Table 2).
These results suggest that a splicing switch from ITSN1-L to ITSN1-S favors glioma progression by
modulating pro-invasion features.
The expression of inflammatory genes modulates the TME in several cancers, including GBM.
The tumor suppressor Kruppel-like factor 6 gene (KLF6) encodes for a transcription factor that
promotes expression of negative regulators of NF-κB, a master regulator of pro-inflammatory cytokines.
Notably, KLF6 is often deleted in GBM [91]. Moreover, KLF6-expressing GBMs often express a
dominant-negative splice variant (KLF6-SV1), which is mislocalized to the cytoplasm and antagonizes
the tumor suppressor activity of the full-length KLF6 protein (KLF6-FL) [92]. KLF6-SV1 lacks the
anti-inflammatory function of the full-length protein and correlates with a more aggressive behavior
and drug-resistance in GBM [91,93], suggesting that its impact on cytokine expression favors the
establishment of a more malignant TME (Table 2).
Estrogen-related receptor β ERR-β (ESRRB), a member of orphan nuclear receptor superfamily,
is alternatively spliced at the 3’-end, leading to the production of several splicing variants [94].
Among them, ERRβ-2 shows pro-apoptotic features and interacts with the actin nucleation-promoting
factor cortactin [95] (Table 2). Cortactin regulates membrane trafficking and the secretion of matrix
metalloproteinases (MMPs) that regulate ECM degradation [96]. Moreover, it promotes invasion and
migration of glioma cells [97]. Since ERRβ-2 suppresses GBM cell migration, this splice variant may
exert its role by limiting the activity of cortactin in GBM cells. Cortactin has been also implicated
in release of extracellular vesicles (EVs) in the TME [98]. EVs are key messengers of intercellular
communications that control the establishment and maintenance of TME [99], are actively secreted by
GBM cells, and promote their oncogenic features [100–103]. For instance, GBM-secreted EVs stimulate
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recipient astrocytes to acquire a pro-tumoral phenotype by delivering several factors, including MYC
and MYCN [101]. Furthermore, EV-mediated transfer of splicing factors from apoptotic to healthy
GBM cells has also been proposed as a mechanism to alter splicing patterns and to promote malignancy.
EVs released by apoptotic GBM cells were enriched in core spliceosomal proteins and snRNAs. Once
internalized in healthy GBM cells, these factors altered the splicing program of recipient cells and
promoted a mesenchymal-like phenotype [102]. In particular, it was shown that the transfer of the
splicing factor RBM11 promoted cell proliferation and chemoresistance of surviving GBM cells by
altering the splicing of cancer-related genes towards more oncogenic isoforms [102] (Table 2).
Collectively, these observations suggest that splicing dysregulation in brain tumors elicits a direct
impact on TME features, which generally favors progression to more aggressive stages.
6. Back Splicing in Brain Tumors
Circular RNAs (circRNAs) are endogenous RNAs derived from a back-splicing process
(i.e., the covalent joining of a downstream splice donor site with an upstream splice acceptor site).
CircRNA biogenesis is mediated by the canonical spliceosome and regulated by the same cis-regulatory
elements and trans-acting factors that control linear splicing [104]. The presence of repetitive elements
in an opposite orientation in distant introns, as well as the dimerization of specific RNA binding
proteins that bind to intronic sites, have been shown to promote circRNA biogenesis [104]. Since
alternative circRNAs can be produced from the same gene, similarly to the splicing of linear transcripts,
and circRNA biogenesis utilizes the same machinery and cis-regulatory elements of linear splicing,
it can be considered as an additional form of alternative splicing.
Even if the majority of circRNAs still lack functional annotations, recent observations reveal
some potentially important roles in gene regulation [104]. For instance, a set of intron-containing
circRNAs regulate gene transcription in cis by directly interacting with the elongating RNA polymerase
II (RNAPII) complex [105] or with the U1 snRNP [106]. CircRNAs biogenesis can also compete with
pre-mRNA splicing, resulting in lower levels of linear mRNAs that include circularized exons [107,108].
Furthermore, circRNAs can function as sponge for microRNAs (miRNAs) [109] or RNA binding
proteins, thereby regulating intracellular mRNA fate [107,110,111]. Lastly, some circRNAs, that contain
AUG sites and internal ribosome entry site (IRES) elements can be translated in small peptides, thus to
expand their regulatory repertoire [112–114].
CircRNAs are aberrantly expressed in several types of cancer, where they regulate multiple
biological processes [115], including in brain tumors [116–118] (Table 2). For instance, circSMARCA5
was identified as one of the circRNAs most differentially expressed in a cohort of fifty-six GBM
patient biopsies. CircSMARCA5 expression negatively correlated with histological grade, with a
strong down-regulation in higher grade. This observation correlated with the reduced migration
capacity/propensity of GBM cells over-expressing circSMARCA5. Interestingly, circSMARCA5 acts as a
sponge for the oncogenic splicing factor SRSF1, thus limiting its activity [119,120]. SRSF1 is up-regulated
in GBM patients and promotes pro-angiogenic VEGF isoforms [120,121]. Thus, down-regulation of
circSMARCA5 in GBM unleashes a trans-acting splicing regulator to promote pro-angiogenic features.
On the other hand, the circNT5E RNA plays oncogenic functions in GBM. CircNT5E controls multiple
pathologic processes, including cell proliferation, migration, and invasion, by directly sponging
miR-422a and inhibiting its activity. Furthermore, circNT5E was observed to sponge other miRNAs,
suggesting the existence of a more complex regulatory network controlled by circNT5E in GBM [122].
Some circRNAs may also encode proteins, which in turn directly regulate cellular processes in
normal brain tissue and glioma. The circFBXW7 RNA encodes a novel 21-kDa protein, called
FBXW7-185aa, which reduces the half-life of c-MYC, thus inhibiting the proliferation of GBM
cells. Accordingly, expression of circFBXW7 is positively associated with overall survival in GBM
patients [123] (Table 2). The circRNA generated by the long intergenic non-protein-coding RNA
p53-induced transcript (LINC-PINT) also encodes for a peptide that acts as tumor suppressor by
reducing the proliferation rate of GBM cells. Expression of this circRNA is strongly reduced in GBM
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compared to healthy tissues and the encoded protein directly interacts with the polymerase associated
factor complex (PAF1c) and inhibits transcriptional elongation of numerous oncogenes [124] (Table 2).
Furthermore, some circRNAs may affect the tumorigenicity and/or the malignant behavior of GBM
cells by regulating, directly or indirectly, the activity of their linear counterpart. This is the case of a
novel 17-kDa protein, called SHPRH-146aa, encoded by the circRNA produced from the SNF2 histone
linker PHD RING helicase gene (SHPRH). It is noteworthy that the start AUG codon and the stop UGA
codon of the open reading frame used for the SHPRH-146aa peptide overlap, as both use the same A
base [125]. Mechanistically, SHPRH-146aa stabilizes the SHPRH full-length protein by inhibiting its
proteasome-dependent degradation. In turn, the SHPRH protein reduces proliferation of GBM cells by
promoting degradation of the proliferating cell nuclear antigen (PCNA) [125] (Table 2).
7. Therapeutic Approaches
Primary and secondary brain tumors can be classified from grade I to grade IV, according to
their proliferative and infiltrative potential (Table 1) [1]. Current therapies include tumor surgical
resection, ionizing radiation and chemotherapy. Despite these invasive treatments, the overall outcome
is ineffective for most of these tumors. Moreover, predictive and reliable markers of therapy response
are urgently needed.
The association between splicing dysregulation and malignancy suggests that brain tumors
might benefit from splicing targeted therapies. To date, several splicing-based pre-clinical approaches
are being developed, and some have already entered the clinical practice [16]. In some cases, these
approaches have been also applied to brain tumors, eliciting promising pre-clinical results. In particular,
ASOs targeting both protein-coding and regulatory non-coding RNA [126,127], sense oligonucleotides
acting as decoy for specific splicing factors [128], or small drugs that modulate the activity of the
spliceosome [53] have been tested in brain tumor models.
Splice switching oligos (SSOs) are ASOs designed to force the production of selected splicing
isoforms. SSOs anneal to the complementary sequence of the target pre-mRNA and inhibit binding
of splicing factors or spliceosomal components, thus allowing inclusion/skipping of selected exons.
This approach has proved to be an efficient therapeutic strategy in neurodegenerative diseases, such
as spinal muscular atrophy [126]. Recently, pre-clinical studies have tested this technology also in
brain tumors (Table 2). Alternative selection of the two last exons in the MNK2 kinase gene (MKNK2)
yields either the MNK2a variant, which displays tumor suppressor activity, or the pro-oncogenic
MNK2b variant. In vivo delivery of an SSO that efficiently promotes splicing of MNK2a inhibited GBM
growth and sensitized GBM cells to chemotherapeutic agents [129]. Comparable anti-cancer results
were obtained by employing the same strategy to promote splicing of a truncated inactive telomerase
subunit (hTERT). The hTERT ASO (AON-Ex726) inhibited proliferation and induced apoptosis of GBM
cells by reducing the levels of the full-length hTERT isoform [130].
ASO that interfere with miRNAs can also indirectly modulate splicing. The expression of mir-10b
is up-regulated in both primary and metastatic brain tumors [131]. ASO-mediated reduction of miR-10b
levels impaired glioma cell viability without affecting survival of normal brain cells. Interestingly, in
this condition the most de-repressed genes were splicing factors that are normally down-regulated in
GBM, suggesting that the oncogenic function of miR-10b partially relies on splicing regulation [132]
(Table 2).
Decoy RNA oligonucleotides (DROs) that specifically interfere with the activity of selected splicing
factors have been recently developed. DROs are modified RNA molecules composed of a tandem
binding motif for a specific splicing factor. The binding of splicing factors to DROs titers them out and
inhibits their splicing activity towards endogenous targets [128]. This strategy was successfully used
to target the activity of the splicing factors RBFOX1/2, PTBP1, and SRSF1. Importantly, the intracranial
injection of an SRSF1-targeted DRO in a GBM mouse model decreased the oncogenic properties of
cancer cells by reverting the splicing of oncogenic splice variants of SRSF1-target genes (INSR, U2AF1,
MKNK2, USP8; see Table 2) [128].
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Table 2. List of the main oncogenic splice variants and splicing-related molecules described in the text.
Spliced Isoform Tumor Type Splicing Factor/ASO 1/DRO 2 Biological Function Reference
BAF45d/6A- GBM 3, GSC PTBP1
Cell growth, self-renewal,
and tumorigenicity [44]
PKM2 GBM PTBP1, hnRNPA1,hnRNPA2 Cell metabolism [45,46]
ETV1-E7, PUM2-E13,
SMN-E6, NDE1-E9,
PKM2
GBM, GSC 4 SRSF3
Cell growth, self-renewal, metabolism
and tumorigenicity [47,48]
PKM1 GBM 10W45-59 and10M46-60 ASOs
Apoptosis [49]
KAP (d variant) GBM unknown Cell proliferation and migration [50]
MADD/E16- GBM hnRNPH Cell proliferation and apoptosis [51]
MYO1B-FL GBM SRSF1 Cells proliferation, survival,and invasion [35]
∆MAX GBM hnRNPA1 Cell metabolism [62]
ANXA7-I2 GBM PTBP1 Membrane trafficking [43]
CD44s GBM unknown EGFR degradation [66]
TAZ Glioma USP39 Cell proliferation [73]
PMEPA1a Glioma unknown Cell proliferation [74]
tGLI1 GBM, MB 5 unknown Angiogenesis and cell growth [79]
L-VEGF144a GBM unknown
Angiogenesis and therapeutic
response [85,86]
ITSN1-L Glioma unknown Cell migration, invasion and adhesion [90]
KLF6-SV1 GBM unknown Inflammatory response [91–93]
ERRβ-2 GBM SRSF6 Apoptosis and cell migration [95]
CyclinD1a, MDM4s,
PKM2 GBM RBM11
Cell proliferation and
chemoresistance [102]
circSMARCA5 GBM unknown Cell migration and angiogenesis [119,120]
circNT5E GBM unknown Cell proliferation, migration,and invasion [122]
circFBXW7 GBM unknown Cell proliferation [123]
circLINC-PINT GBM unknown Transcriptional elongation [124]
circSHPRH GBM unknown Cell proliferation [125]
MNK2a GBM 2b-block SSO Cell growth and chemotherapeuticresponse [129]
trunc-hTERT GBM AON-Ex726 SSO Cell proliferation and apoptosis [130]
SRSF1-target genes GBM SF2i1 and SF2i2DROs p38-MAPK pathway [128]
1 ASO: antisense oligonucleotide; 2 DRO: Decoy RNA oligonucleotides; 3 GBM: glioblastoma; 4 GSC: glioma stem
cell; 5 MB: medulloblastoma.
These observations suggest that RNA-based therapeutic strategies may be useful to counteract
brain tumorigenesis. The selective nature of RNA-RNA interactions makes these molecules highly
specific for their targets, thus reducing broad cellular detrimental effects. This is exemplified by the
excellent results obtained by Nusinersen, an SSO that rescues exon 7 splicing in the SMN2 gene,
in patients affected by Spinal Muscular Atrophy [126]. However, the major current limit to strategies
based on SSOs and DROs is represented by their delivery, as they should be modified to allow for
crossing of the blood–brain barrier in order to avoid intrathecal injections in patients.
Approaches to more globally target splicing regulation by chemical inhibitors for the spliceosome
machinery are also being evaluated in brain tumors. In this regard, a promising target is PRMT5,
a type II methyltransferase that is responsible for depositing the majority of the symmetrical
dimethylation marks on arginines (SDMA) and methylates several RNA binding proteins and
spliceosomal proteins [133–135]. In MYC-driven tumors, PRMT5 enhances assembly of spliceosome
components and MYC expression [136,137]. Since MYC promotes GBM cell survival, proliferation,
invasiveness, and self-renewal, its expression is inversely correlated with patient survival [53,138–140].
PRMT5 inhibition in GBM causes the accumulation of intron-containing pre-mRNAs, mainly affecting
genes involved in cell-cycle progression, chromosome segregation, RNA biology, and DNA repair.
These observations suggest that GBM is highly dependent on PRMT5 up-regulation to ensure efficient
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splicing [53] and that it might be a promising therapeutic target for MYC-driven tumors [141,142]
(Figure 3). Indeed, MYC up-regulation induces a pervasive activation of gene transcription and it is
likely that cells need to coordinate this transcriptional burden with an efficient RNA processing rate.
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and DNA replication and repair). EPZ015666 and CMP5 dependent PRMT5 inhibition causes the
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Specific inhibitors of PRMT5 activity have been recently developed. Two of these, EPZ015666
and CMP5, have shown promising results in GBM, as they efficiently reduced tumor growth in both
in vitro and in vivo models [53,138]. Moreover, three PRMT5 inhibitors [GSK3326595 (clinicaltrials.gov
NCT02783300), PF 06,939,999 (clinicaltrials.gov NCT03854227), and JNJ-64619178 (clinicaltrials.gov
NCT03573310)] are in phase I clinical trials for patients with advanced solid tumors [143]. Since
non-tumoral cells express low levels of PRMT5, these inhibitors may show limited cellular toxicity
and high cancer cell specificity. These features may favor their employment in novel therapeutic
approaches for cancers that are unresponsive to conventional therapies, either as single agents or in
combined regimens.
8. Conclusions
Alternative splicing is a versatile mechanism utilized by eukaryotic cells to finely tune gene
expression. As most human genes undergo alternative splicing, virtually every cellular pathway is
regulated by this process. Mounting evidence indicates that alternative splicing regulation is a sensitive
mechanism employed by cells to integrate the responses to environmental and endogenous cues. Brain
tumors, and in particular GBM and SHH-MB, have been recently shown to rely on altered splicing
regulation for their onset or progression. At the same time, splicing dysregulation is emerging as a
vulnerability of brain cancer cells that can be exploited therapeutically. Herein, we have discussed how
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deregulated cellular signals drive aberrant pro-oncogenic splicing programs in brain tumors, and the
way in which oncogenic splice variants interfere with key cellular processes. Moreover, in some cases,
such as SHH-MB, mutations in spliceosome components represent a driver event in tumorigenesis, with
broad consequences on the transcriptome of cancer cells. Collectively, the examples described in this
study indicate that brain tumors rely on the modulation of alternative splicing to promote and sustain
cancer cell proliferation, as well as to shape the tumor environment and favor cancer cell survival.
Although a direct comparison of the relative impact of transcription and splicing dysregulation in
brain tumors has not been performed yet, it is likely that the two pathways cooperate. Indeed, splicing
is mechanistically coupled to transcription and, in turn, splicing factors elicit widespread effects on
transcription [144]. This tight connection between the transcription and processing of nascent RNAs
needs to be precisely controlled in order to avoid detrimental effects originating from the expression of
aberrant gene products.
The increasing interest in splicing regulation observed in the past decade has clarified many
aspects of this sophisticated mechanism. Nevertheless, further efforts are still necessary to clarify the
paramount impact of splicing dysregulation in brain tumors and to assess the potential of targeting
this process as an efficacious therapeutic approach for these neoplastic diseases.
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